First patients in the U.S. treated with OssDsign Catalyst

OssDsign Catalyst received market clearance from the Food and Drug Administration (FDA) in 2020 and was launched on the American market in august 2021. The addressable market for synthetic bone grafts after spinal fusion surgeries is valued at USD 2.6 billion and has a CAGR of approximately 7% during the period 2021–2025.

“We are happy to mark the start of surgeries being performed with OssDsign Catalyst in the US. This means that our innovative synthetic bone graft is now being used in patient treatment, confirming the need for new and effective solutions for spinal fusion surgeries. We are convinced that OssDsign Catalyst will improve the clinical outcome for many patients ahead,” comments Morten Henneveld, CEO, OssDsign.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.